Over the past few months, Novartis has struggled with a string of problems at several manufacturing plants. Notably, a facility in Nebraska suffered embarrassing gaffes involving over-the-counter meds and animal health drugs (see this and this). And the FDA sent a warning letter last November for “significant violations” at two other US plants – Broomfield, Colorado and Wilson, North Carolina. A Sandoz plant in Quebec, Canada, meanwhile, has since halted some production.However, the drugmaker is having an equally rough time in Europe, where shortages are reported in several countries, including Austria, Belgium, Bulgaria, Czech Republic, Germany, Spain, France, Hungary, Ireland, Italy, Netherlands, Poland, Portugal, Romania, Slovenia and Slovakia, according to Polish media.